Perioperative and Maintenance Therapy after First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages 302-308

  Hoffman Censits, Jean ^a   Wong, Yu Ning ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Adjuvant therapy; Maintenance therapy; Neoadjuvant chemotherapy; Targeted therapy; Urothelial cancer

Indexed keywords

ANTIEMETIC AGENT; APATORSEN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GROWTH FACTOR; IPILIMUMAB; K RAS PROTEIN; LENALIDOMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PEMETREXED; PLACEBO; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONSTIPATION; CYSTECTOMY; CYTOPENIA; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW RISK PATIENT; LYMPH VESSEL METASTASIS; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; MYALGIA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; REVIEW; RISK REDUCTION; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; PERIOPERATIVE PERIOD; URINARY BLADDER NEOPLASMS;

EID: 84936986104     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.03.003     Document Type: Review

References (49)

1. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
2. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
3. A.B. Apolo, J.W. Kim, and B.H. Bochner Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States Urol Oncol 32 2014 637 644
4. Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. In press.
5. C.N. Sternberg, P. de Mulder, and J.H. Schornagel EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50 54
6. E.R. Plimack, J.H. Hoffman-Censits, and R. Viterbo Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 2014 1895 1901
7. T.K. Choueiri, S. Jacobus, and J. Bellmunt Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates J Clin Oncol 32 2014 1889 1894
8. Siefker-Radtke A, Kamat A, Corn P, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the University of Texas MD Anderson Cancer Center. ASCO Meeting Abstracts 2012; 30:4523.
9. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group G. Griffiths, R. Hall, and R. Sylvester International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
10. H.J. Lavery, K.D. Stensland, and G. Niegisch Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate J Urol 191 2014 898 906
11. G. Sonpavde, B.H. Goldman, and V.O. Speights Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
12. F. Petrelli, A. Coinu, and M. Cabiddu Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis Eur Urol 65 2014 350 357
13. W. Kassouf, P.E. Spiess, and G.A. Brown P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors Eur Urol 52 2007 769 774
14. R. Rosenblatt, A. Sherif, and E. Rintala Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
15. D. Tilki, R.S. Svatek, and G. Novara Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients J Urol 184 2010 888 894
16. D.D. Chism, M.E. Woods, and M.I. Milowsky Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer Oncologist 18 2013 933 940
17. R.S. Pruthi, M. Nielsen, and S. Heathcote A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results BJU Int 106 2010 349 354
18. Hahn N, Daneshmand S, Posadas E, et al. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. ASCO Meeting Abstracts 2012; 30:4586.
19. Knudsen B, Hahn NM, Daneshmand S, et al. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). ASCO Meeting Abstracts 2014; 32:324.
20. Plimack E, Gupta S, Bellmunt J, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer. Paper presented at: ESMO Annual Meeting; 2014; Madrid, Spain.
21. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2014; 32:5011.
22. W. Choi, S. Porten, and S. Kim Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
23. K.L. Yap, K. Kiyotani, and K. Tamura Whole exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival Clin Cancer Res 20 2014 6605 6617
24. M.F. Ozcan, O. Dizdar, and N. Dincer Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy Urol Oncol 31 2013 1709 1715
25. E. Plimack, R. Dunbrack, and T. Brennan Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC) ASCO Meeting Abstracts 32 2014 4538
26. C.N. Sternberg, I. Skoneczna, and J.M. Kerst Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Lancet Oncol 16 2015 76 86
27. F. Cognetti, E.M. Ruggeri, and A. Felici Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial Ann Oncol 23 2012 695 700
28. W.M. Stadler, S.P. Lerner, and S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
29. J.J. Leow, W. Martin-Doyle, and P.S. Rajagopal Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials Eur Urol 66 2014 42 54
30. Galsky M, Stensland K, Moshier E, et al. Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with >= pT3 and/or pN+ bladder cancer (BCa). ASCO Meeting Abstracts 2015, 33:292.
31. P.D. Grivas, S. Daignault, and S.T. Tagawa Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma Cancer 120 2014 692 701
32. N. Agarwal, A.B. Apolo, and C.K. Tsao Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma Oncologist 19 2014 915 916
33. Polo SH, Gonzalez del Alba A, Perez-Valderrama B, et al. Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: a phase II, randomized, open label, study (MAJA study, SOGUG 2011-02) - interim analysis on safety. ASCO Meeting Abstracts 2014; 32:359.
34. A.D. Seidman The search for an elusive uniform strategy for a heterogeneous disease: lesson learned? J Clin Oncol 31 2013 1707 1708
35. R.F. Ozols Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit J Clin Oncol 21 2003 2451 2453
36. K.E. Oliver, and W.P. McGuire Ovarian cancer and antiangiogenic therapy: caveat emptor J Clin Oncol 32 2014 3353 3356
37. M. Markman, P.Y. Liu, and S. Wilczynski Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 2003 2460 2465
38. C. Tournigand, A. Cervantes, and A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study J Clin Oncol 24 2006 394 400
39. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
40. T.J. Perren, A.M. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
41. A. du Bois, A. Floquet, and J.W. Kim Incorporation of pazopanib in maintenance therapy of ovarian cancer J Clin Oncol 32 2014 3374 3382
42. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
43. M. Reck, J. von Pawel, and P. Zatloukal Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
44. M.D. Galsky, E. Moshier, and S. Krege Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy Urol Oncol 32 2014 48.e1 48.e8
45. L.L. Siu, J.D. Shapiro, and D.J. Jonker Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial J Clin Oncol 31 2013 2477 2484
46. J. Ledermann, P. Harter, and C. Gourley Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol 15 2014 852 861
47. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
48. D.J. Vaughn, C.M. Broome, and M. Hussain Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer J Clin Oncol 20 2002 937 940
49. C.J. Sweeney, B.J. Roth, and F.F. Kabbinavar Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451 3457